Friday, 18th May – h. 12:00
Seminars Room, NICO
APP and Presenilins: biological function and role in neurodegenerative and neuromuscular diseases
The major role of the Amyloid Precursor Protein (APP) in the onset and progression of Alzheimer's disease (AD) has been revealed almost three decades ago by the combination of genetic and biochemical approaches, leading to the amyloid cascade hypothesis. Similarly to APP, Presenilins (PSs), the catalytic core of the multiprotein enzymatic complex (β-secretase) generating the beta-amyloid peptide (Aβ), are mainly studied for their role in the ultimate step of APP amyloidogenic processing.
Apart from generating Aβ, the major constituent of senile plaques that are typical AD lesions directly related to AD onset and progression, the pivotal physiological role of APP and how PSs could impact it remains scarcely known or controversial. A leading hypothesis suggests that APP function relies on the transcriptional regulation that APP exerts on a set of target genes, the so-called APP target genes.
In this context, we contributed to a more comprehensive picture of APP regulatory network and physiological function by showing that APP-dependent regulation of the Glial cell line-Derived Neurotrophic Factor (GDNF) drives the process of neuronal and muscular maturation involved in neuromuscular junctions (NMJs) formation (Stanga et al. FASEB J 2016). APP-dependent GDNF transcription appears as critical for the muscular phenotype observed in APP null transgenic mice (APP-/-).
Moreover, in a non-biased transcriptome analysis, we observed that GDNF transcription is strongly reduced in PSs deficient mouse embryonic fibroblasts (MEFs); interestingly, Presenilin 2 (PS2) appears to be predominant in this process.
It is therefore of particular significance to understand the molecular mechanisms recruited by APP/PS2 to control the expression of the GDNF, a neurotrophic factor fundamental for both central nervous system (CNS) and peripheral nervous system (PNS) neuron survival and, importantly, altered in AD and amyotrophic lateral sclerosis (ALS).
Host: Alessandro Vercelli
Since 2001, this meeting represented an important event for basic and clinical researchers working on this emerging scientific topic. We will address state-of-the-art approaches in the field of steroids and nervous system, including behavior, epigenetics, genomic and non-genomic actions, the vitamin D, neurodegenerative and psychiatric disorders, and the interference among endocrine disruptors and steroid signaling.
L’inibizione della proteina JNK rallenta la progressione della malattia che colpisce i motoneuroni ed è la prima causa genetica di morte nell’infanzia. Lo dimostra uno studio pubblicato su Frontiers in Molecular Neuroscience dal nostro gruppo di ricerca guidato da Alessandro Vercelli, in collaborazione con l’Istituto Mario Negri di Milano. Chiarire i meccanismi molecolari alla base della SMA può aprire la strada allo sviluppo di nuove terapie.